Work

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-167468

Authors: Justin Watts, Michael Maris, Tara L. Lin, Prapti Patel, Yazan F. Madanat, Christopher R. Cogle, Gautam Borthakur, Dirk Huebner, Noor Khaskhely, Lynn Bonham, Monica Massaro, Daphne Taylor, Caroline Taromino, Alice S. Mims

Institutions: University of Miami, Sylvester Comprehensive Cancer Center, University of Kansas, The University of Texas Southwestern Medical Center, University of Florida, The University of Texas MD Anderson Cancer Center, Aptevo Therapeutics (United states), The Ohio State University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310159180

FWCI: 2.659

Cites:

Cited by: 22

Related to: 10